Adage Capital Partners Gp, L.L.C. Bristol Myers Squibb CO Transaction History

Adage Capital Partners Gp, L.L.C.

$54.9 Billion
Q4 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 7,769,227 shares of BMY stock, worth $434 Million. This represents 0.8% of its overall portfolio holdings.

Number of Shares

7,769,227

Previous 4,494,166 72.87%

Holding current value

$434 Million

Previous $233 Million 88.94%

% of portfolio

0.8%

Previous 0.43%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$51.92 - $59.94 $170 Million - $196 Million	3,275,061 Added 72.87%	7,769,227 $439 Million
Q3 2024 Nov 14, 2024	BUY	$39.66 - $51.75 $144 Million - $187 Million	3,622,532 Added 415.6%	4,494,166 $233 Million
Q2 2024 Aug 14, 2024	BUY	$40.25 - $52.99 $35.1 Million - $46.2 Million	871,634 New	871,634 $36.2 Million
Q3 2023 Nov 14, 2023	BUY	$57.89 - $64.73 $9.27 Million - $10.4 Million	160,188 New	160,188 $9.3 Million
Q1 2023 May 15, 2023	SELL	$65.71 - $74.53 $29 Million - $32.9 Million	-440,848 Reduced 51.64%	412,918 $28.6 Million
Q4 2022 Feb 14, 2023	SELL	$68.48 - $81.09 $94 Million - $111 Million	-1,372,229 Reduced 61.65%	853,766 $61.4 Million
Q3 2022 Nov 14, 2022	BUY	$0.13 - $76.84 $159,761 - $94.4 Million	1,228,935 Added 123.26%	2,225,995 $158 Million
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $31.2 Million - $34.4 Million	430,260 Added 75.91%	997,060 $76.8 Million
Q1 2022 May 16, 2022	BUY	$61.48 - $73.72 $3.87 Million - $4.64 Million	62,900 Added 12.48%	566,800 $41.4 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $16.6 Million - $19.4 Million	-309,539 Reduced 38.05%	503,900 $31.4 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $33.1 Million - $38.8 Million	-559,300 Reduced 40.74%	813,439 $48.1 Million
Q2 2021 Aug 16, 2021	SELL	$61.91 - $67.42 $4.11 Million - $4.48 Million	-66,400 Reduced 4.61%	1,372,739 $91.7 Million
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $26.5 Million - $29.8 Million	-447,100 Reduced 23.7%	1,439,139 $90.9 Million
Q4 2020 Feb 16, 2021	SELL	$57.74 - $65.43 $19 Million - $21.6 Million	-329,565 Reduced 14.87%	1,886,239 $117 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $127 Million - $141 Million	2,215,804 New	2,215,804 $134 Million
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $120 Million - $141 Million	-2,197,289 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$46.4 - $67.43 $475,600 - $691,157	-10,250 Reduced 0.46%	2,197,289 $122 Million
Q4 2019 Feb 14, 2020	BUY	$49.21 - $64.19 $109 Million - $142 Million	2,207,539 New	2,207,539 $142 Million
Q2 2019 Aug 14, 2019	SELL	$44.62 - $49.34 $38 Million - $42 Million	-851,920 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$45.12 - $53.8 $42.1 Million - $50.2 Million	-933,705 Reduced 52.29%	851,920 $40.6 Million
Q4 2018 Feb 14, 2019	BUY	$48.76 - $63.23 $1.21 Million - $1.56 Million	24,735 Added 1.4%	1,785,625 $92.8 Million
Q3 2018 Nov 14, 2018	BUY	$55.19 - $62.25 $6.85 Million - $7.73 Million	124,180 Added 7.59%	1,760,890 $109 Million
Q2 2018 Aug 14, 2018	SELL	$50.53 - $62.98 $55.5 Million - $69.1 Million	-1,097,640 Reduced 40.14%	1,636,710 $90.6 Million
Q1 2018 May 15, 2018	BUY	$59.92 - $68.98 $24.4 Million - $28.1 Million	407,846 Added 17.53%	2,734,350 $173 Million
Q4 2017 Feb 14, 2018	BUY	$59.94 - $65.35 $28 Million - $30.5 Million	466,920 Added 25.11%	2,326,504 $143 Million
Q3 2017 Nov 14, 2017	BUY	$55.23 - $63.74 $103 Million - $119 Million	1,859,584	1,859,584 $119 Million

Others Institutions Holding BMY

# of Institutions

2,751

Shares Held

1.57B

Call Options Held

28M

Put Options Held

28.7M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $119B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Bristol Myers Squibb CO Transaction History